SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al.2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care Res (Hoboken)2012;64:62539.
  • 2
    Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Arthritis Rheum2008;59:76284.
  • 3
    Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al.Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.Arthritis Rheum2007;57:92834.
  • 4
    Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al.Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.JAMA2011;305:4806.
  • 5
    Solomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN.Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey.Arthritis Care Res (Hoboken)2012;64:1849.
  • 6
    Yelin EH, Henke CJ, Kramer JS, Nevitt MC, Shearn M, Epstein WV.A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices.N Engl J Med1985;312:9627.
  • 7
    Yelin EH, Criswell LA, Feigenbaum PG.Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings.JAMA1996;276:104853.
  • 8
    Katz PP, Morris A, Yelin EH.Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis.Ann Rheum Dis2006;69:18038.
  • 9
    Armitage P.Tests for linear trends in proportions and frequencies.Biometrics1955;11:37586.
  • 10
    Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A.Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.J Rheumatol2009;36:16117.
  • 11
    Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, van Staa TP, et al.The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database.Rheumatology (Oxford)2005;44:13948.
  • 12
    Lacaille D, Anis AH, Guh DP, Esdaile JM.Gaps in care for rheumatoid arthritis: a population study.Arthritis Rheum2005;53:2418.
  • 13
    Ziegler S, Huscher D, Karberg K, Krause A, Wassenberg S, Zink A.Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres.Ann Rheum Dis2010;69:18038.